Regulation & law · 19/12/1996Updated: 10/18/2026 · 1 min read
SmithKline Beecham Biologicals S.A. to Receive Exclusive Patent License for Malaria Vaccine
Summary
The US Department of the Navy is granting SmithKline Beecham Biologicals S.A. a non-transferable, exclusive license to develop and use a malaria vaccine based on a patented protein, with a 60-day objection period.
Original source language: Federal Register — All DocumentsOpen original release →